Patents by Inventor Marc A. Labroli

Marc A. Labroli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240059693
    Abstract: The present invention relates to novel Fused Bicyclic Pyrazole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. The present invention also relates to compositions comprising at least one Fused Bicyclic Pyrazole Derivative, and methods of using the Fused Bicyclic Pyrazole Derivatives for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 22, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ronald K. Chang, Andrew J. Cooke, JR., Christopher Douglas Cox, Marc Labroli, Izzat Tiedje Raheem, Jack D. Scott, Jeffrey W. Schubert, Jason W. Skudlarek, Zheng Tan, Ling Tong
  • Patent number: 11752128
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: September 12, 2023
    Assignee: MERCK SHARP & DOHME CORPORATION
    Inventors: John P. Caldwell, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Jianping Pan, Weidong Pan, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Hao Wang, Christine Yang, Shu-Wei Yang
  • Patent number: 11738010
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: August 29, 2023
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: John P. Caldwell, Reynalda De Jesus, Fa-Xiang Ding, Charles J. Gill, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Haifeng Tang, Hao Wang, Christine Yang, Shu-Wei Yang
  • Publication number: 20230077499
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, and R4 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 16, 2020
    Publication date: March 16, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Andrew John Cooke, Robert Patrick Hayes, Marc A. Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Jeffrey W. Schubert, David M. Tellers
  • Publication number: 20230054782
    Abstract: The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compositions comprising at least one Bicyclic Heterocycle Compound, and methods of using the Bicyclic Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 17, 2020
    Publication date: February 23, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Andrew John Cooke, Brendan M. Crowley, Marc A. Labroli, Michael Aaron Plotkin, Izzat T. Raheem, Ling Tong, Deyou Sha
  • Patent number: 11413292
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R1 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 16, 2022
    Assignee: Merck, Sharp & Dohme LLC
    Inventors: Mark W. Embrey, Timothy John Hartingh, Marc Labroli, Izzat T. Raheem
  • Publication number: 20210361662
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R1 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: February 11, 2019
    Publication date: November 25, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark W. Embrey, Timothy John Hartingh, Marc Labroli, Izzat T. Raheem
  • Publication number: 20210346364
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Application
    Filed: July 26, 2021
    Publication date: November 11, 2021
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: John P. CALDWELL, Reynalda DE JESUS, Fa-Xiang DING, Charles J. GIll, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Terry ROEMER, Jing SU, Christopher Michael TAN, Zheng TAN, Haifeng TANG, Hao WANG, Christine YANG, Shu-Wei YANG
  • Publication number: 20210346344
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Application
    Filed: July 26, 2021
    Publication date: November 11, 2021
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: John P. CALDWELL, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Jianping PAN, Weidong PAN, Terry ROEMER, Jing SU, Christopher Michael TAN, Zheng TAN, Hao WANG, Christine YANG, Shu-Wei YANG
  • Patent number: 11141410
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: October 12, 2021
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: John P. Caldwell, Reynalda De Jesus, Fa-Xiang Ding, Charles J. Gill, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Haifeng Tang, Hao Wang, Christine Yang, Shu-Wei Yang
  • Patent number: 11141403
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: October 12, 2021
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: John P. Caldwell, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Jianping Pan, Weidong Pan, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Hao Wang, Christine Yang, Shu-Wei Yang
  • Publication number: 20200261436
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Application
    Filed: December 13, 2016
    Publication date: August 20, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: John P. CALDWELL, Reynalda DE JESUS, Fa-Xiang DING, Charles J. GIll, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Terry ROEMER, Jing SU, Christopher Michael TAN, Zheng TAN, Haifeng TANG, Hao WANG, Christine YANG, Shu-Wei YANG
  • Publication number: 20200261410
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Application
    Filed: December 13, 2016
    Publication date: August 20, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: John P. CALDWELL, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Jianping PAN, Weidong PAN, Terry ROEMER, Jin SU, Christopher Michael TAN, Zheng TAN, Hao WANG, Christine YANG, Shu-Wei YANG
  • Patent number: 9206142
    Abstract: The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: December 8, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gerald W. Shipps, Jr., Cliff C. Cheng, Xiaohua Huang, Thierry O. Fischmann, Jose S. Duca, Matthew Richards, Hongbo Zeng, Binyuan Sun, Panduranga Adulla Reddy, Tzu T. Wong, Praveen K. Tadikonda, M. Arshad Siddiqui, Marc A. Labroli, Cory S. Poker, Timothy J. Guzi
  • Patent number: 8603998
    Abstract: In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: December 10, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Timothy J. Guzi, David A. Parry, Marc A. Labroli, Michael D. Dwyer, Kamil Paruch
  • Patent number: 8586576
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: November 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Kartik M. Keertikar
  • Patent number: 8580782
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: November 12, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc A. Labroli, Kartik M. Keertikar
  • Publication number: 20130196986
    Abstract: The invention provides certain 3,7-disubstituted-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-ones of the Formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R8, and X are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating pain or an inflammatory disease.
    Type: Application
    Filed: September 16, 2011
    Publication date: August 1, 2013
    Inventors: Marc Labroli, Michael F. Czarniecki, Cory Seth Poker
  • Patent number: 8476278
    Abstract: The present invention relates to novel Thiazole Derivatives, compositions comprising the Thiazole Derivatives, and methods for using the Thiazole Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: July 2, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Panduranga Adulla P. Reddy, Tzu T. Wong, Lianyun Zhao, Shuyi Tang, Marc A. Labroli, Timothy J. Guzi, M. Arshad Siddiqui
  • Publication number: 20120328691
    Abstract: The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.
    Type: Application
    Filed: October 29, 2007
    Publication date: December 27, 2012
    Inventors: Gerald W. Shipps, JR., Cliff C. Cheng, Xiaohua Huang, Thierry O. Fischmann, Jose S. Duca, Matthew Richards, Hongbo Zeng, Binyuan Sun, Panduranga Adulla Reddy, Tzu T. Wong, Praveen K. Tadikonda, M. Arshad Siddiqui, Marc A. Labroli, Cory Poker, Timothy J. Guzi